Działania niepożądane statyn – fakty i mity Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2018
Słowa kluczowe:
statyny, działania niepożądane, toksyczność
##plugins.themes.bootstrap3.article.main##
Abstrakt
Chociaż niniejszy artykuł nie opisuje wszystkich rzeczywistych i domniemanych działań niepożądanych związanych z przyjmowaniem statyn, zwrócono w nim uwagę na najważniejsze z nich oraz na ostatnio podnoszone w piśmiennictwie. Przytoczone argumenty – w dobie coraz szerszego użycia tych znakomitych leków, które zrewolucjonizowały profilaktykę chorób układu sercowo-naczyniowego – powinny pomóc lekarzom bezpiecznie je stosować. Należy również podkreślić, że działania niepożądane związane ze statynami występują rzadko, jednak trzeba mieć świadomość, iż mogą dotyczyć naszego pacjenta.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Barylski , M. (2018). Działania niepożądane statyn – fakty i mity . Medycyna Faktów , 11(3(40), 210-215. https://doi.org/10.24292/01.MF.0318.7
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Catapano A.L., Graham I., De Backer G. et al.; 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016; 37(39): 2999-3058.
2. Cannon C.P.: Balancing the benefits of statins versus a new risk-diabetes. Lancet 2010; 375: 700-701.
3. Waters D.D., Ho J.E., DeMicco D.A. et al.: Predictors of new-onset diabetes in patients treated with atorvastatin. Results from 3 large randomized clinical trials. J. Am. Call. Cardiol. 2011; 57: 1535-1545.
4. Law M.R., Wald N.J., Rudnicka A.R. et al.: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. B.M.J. 2003; 326: 1423.
5. Baigent C., Keech A., Kearney P.M. et al.: Efficacy and safety of cholesterol- lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
6. Graham D.J., Staffa J.A., Shatin D. et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-2590.
7. Baigent C., Blackwell L., Emberson J.: Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
8. Aragon G., Younossi Z.M.: When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Clev. Clin. J. Med. 2010; 71: 195-204.
9. Armitage J.: The safety of statins in clinical practice. Lancet 2007; 370: 1781-1790.
10. Calderon R.M., Cubeddu L.X., Goldberg R.B., Schiff E.R.: Statins and the treatment of dyslipidaemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin. Proc. 2010; 85: 349-356.
11. De Denus S., Spinler S.A., Miller K., Peterson A.M.: Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24: 584-591.
12. Newman C., Tsai J., Szarek M. et al.: Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 complete trials in 14 236 patients. Am. J. Cardiol. 2006; 97: 61-67.
13. Silva M., Matthews M.L., Jarvis C. et al.: Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin. Ther. 2007; 29: 253-260.
14. Charles E.C., Olson K.L., Standhoff B.J. et al.: Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am. J. Med. 2005; 118: 618-624.
15. Dujovne C.A.: Side effects of statins: hepatitis versus “transaminitis” – myositis versus “CPKitis”. Am. J. Cardiol. 2002; 89: 1411-1413.
16. Onofrei M.D., Butler K.L., Fuke D.C., Miller H.B.: Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 2008; 15: 921-924.
17. Filipiak K.J., Kapłon-Cieślicka A., Opolski G.: Interakcje lekowe statyn. W: Banach M., Filipiak K.J., Opolski G. (red.): Aktualny stan wiedzy na temat statyn. Termedia, Poznań 2013: 403-424.
18. Rojas-Fernandez C.H., Cameron J.C.F.: Is statin-associated cognitive impairement clinically relevant? A narrative review and clinical recommendations. Ann. Pharmacother. 2012; 46: 549-557.
19. Blais L., Desgagne A., LeLorier J.: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch. Intern. Med. 2000; 160(15): 2363-2368.
20. Graaf M.R., Beiderbeck A.B., Egberts A.C. et al.: The risk of cancer in users of statins. J. Clin. Oncol. 2004; 22(12): 2388-2394.
21. Poynter J.N., Gruber S.B., Higgins P.D. et al.: Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005; 352(21): 2184-2192.
22. Xiao H., Yang C.S.: Combination regimen with statins and NSAIDS: a promising strategy for cancer chemoprevention. Int. J. Cancer. 2008; 123(5): 983-990.
23. Cauley J.A., McTiernan A., Rodabough R.J. et al.: Statin use and breast cancer: prospective results from the Women’s Health Initiative. J. Natl. Cancer Inst. 2006; 98(10): 700-707.
24. Platz E.A., Leitzmann M.F., Visvanathan K. et al.: Statin drugs and risk of advanced prostate cancer. J. Natl. Cancer Inst. 2006; 98(24): 1819-1825.
25. Jacobs E.J., Rodriguez C., Brady K.A. et al.: Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J. Natl. Cancer Inst. 2006; 98(1): 69-72.
26. Kaye J.A., Meier C.J., Walker A.M., Jick H.: Statin use, hyperlipidaemia, and the risk of breast cancer. Br. J. Cancer 2002; 86(9): 1436-1439.
27. Browning D.R., Martin R.M.: Statins and risk of cancer: a systematic review and metaanalysis. Int. J. Cancer 2007; 120(4): 833-843.
28. Bonovas S., Filioussi K., Tsavaris N., Sitaras N.M.: Statins and cancer risk: a literature-based metaanalysis and metaregression analysis of 35 randomized controlled trials. J. Clin. Oncol. 2006; 24(3): 4808-4817.
29. Farwell W.R., Scranton R.E., Lawler E.V. et al.: The association between statins and cancer incidence in a veterans population. J. Natl. Cancer Inst. 2008; 100(2): 134-139.
30. Karp I., Behlouli H., Lelorier J., Pilote L.: Statins and cancer risk. Am. J. Med. 2008; 121(4): 302-309.
2. Cannon C.P.: Balancing the benefits of statins versus a new risk-diabetes. Lancet 2010; 375: 700-701.
3. Waters D.D., Ho J.E., DeMicco D.A. et al.: Predictors of new-onset diabetes in patients treated with atorvastatin. Results from 3 large randomized clinical trials. J. Am. Call. Cardiol. 2011; 57: 1535-1545.
4. Law M.R., Wald N.J., Rudnicka A.R. et al.: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. B.M.J. 2003; 326: 1423.
5. Baigent C., Keech A., Kearney P.M. et al.: Efficacy and safety of cholesterol- lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
6. Graham D.J., Staffa J.A., Shatin D. et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-2590.
7. Baigent C., Blackwell L., Emberson J.: Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
8. Aragon G., Younossi Z.M.: When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Clev. Clin. J. Med. 2010; 71: 195-204.
9. Armitage J.: The safety of statins in clinical practice. Lancet 2007; 370: 1781-1790.
10. Calderon R.M., Cubeddu L.X., Goldberg R.B., Schiff E.R.: Statins and the treatment of dyslipidaemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin. Proc. 2010; 85: 349-356.
11. De Denus S., Spinler S.A., Miller K., Peterson A.M.: Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24: 584-591.
12. Newman C., Tsai J., Szarek M. et al.: Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 complete trials in 14 236 patients. Am. J. Cardiol. 2006; 97: 61-67.
13. Silva M., Matthews M.L., Jarvis C. et al.: Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin. Ther. 2007; 29: 253-260.
14. Charles E.C., Olson K.L., Standhoff B.J. et al.: Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am. J. Med. 2005; 118: 618-624.
15. Dujovne C.A.: Side effects of statins: hepatitis versus “transaminitis” – myositis versus “CPKitis”. Am. J. Cardiol. 2002; 89: 1411-1413.
16. Onofrei M.D., Butler K.L., Fuke D.C., Miller H.B.: Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 2008; 15: 921-924.
17. Filipiak K.J., Kapłon-Cieślicka A., Opolski G.: Interakcje lekowe statyn. W: Banach M., Filipiak K.J., Opolski G. (red.): Aktualny stan wiedzy na temat statyn. Termedia, Poznań 2013: 403-424.
18. Rojas-Fernandez C.H., Cameron J.C.F.: Is statin-associated cognitive impairement clinically relevant? A narrative review and clinical recommendations. Ann. Pharmacother. 2012; 46: 549-557.
19. Blais L., Desgagne A., LeLorier J.: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch. Intern. Med. 2000; 160(15): 2363-2368.
20. Graaf M.R., Beiderbeck A.B., Egberts A.C. et al.: The risk of cancer in users of statins. J. Clin. Oncol. 2004; 22(12): 2388-2394.
21. Poynter J.N., Gruber S.B., Higgins P.D. et al.: Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005; 352(21): 2184-2192.
22. Xiao H., Yang C.S.: Combination regimen with statins and NSAIDS: a promising strategy for cancer chemoprevention. Int. J. Cancer. 2008; 123(5): 983-990.
23. Cauley J.A., McTiernan A., Rodabough R.J. et al.: Statin use and breast cancer: prospective results from the Women’s Health Initiative. J. Natl. Cancer Inst. 2006; 98(10): 700-707.
24. Platz E.A., Leitzmann M.F., Visvanathan K. et al.: Statin drugs and risk of advanced prostate cancer. J. Natl. Cancer Inst. 2006; 98(24): 1819-1825.
25. Jacobs E.J., Rodriguez C., Brady K.A. et al.: Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J. Natl. Cancer Inst. 2006; 98(1): 69-72.
26. Kaye J.A., Meier C.J., Walker A.M., Jick H.: Statin use, hyperlipidaemia, and the risk of breast cancer. Br. J. Cancer 2002; 86(9): 1436-1439.
27. Browning D.R., Martin R.M.: Statins and risk of cancer: a systematic review and metaanalysis. Int. J. Cancer 2007; 120(4): 833-843.
28. Bonovas S., Filioussi K., Tsavaris N., Sitaras N.M.: Statins and cancer risk: a literature-based metaanalysis and metaregression analysis of 35 randomized controlled trials. J. Clin. Oncol. 2006; 24(3): 4808-4817.
29. Farwell W.R., Scranton R.E., Lawler E.V. et al.: The association between statins and cancer incidence in a veterans population. J. Natl. Cancer Inst. 2008; 100(2): 134-139.
30. Karp I., Behlouli H., Lelorier J., Pilote L.: Statins and cancer risk. Am. J. Med. 2008; 121(4): 302-309.